Plain-English translation of NCT06092333 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tests a combination of two medications——for treating chronic hepatitis B in adults who have never received treatment for this condition. The study will enroll 10 participants and track how well this medication combination reduces the virus in the blood and liver over time. Researchers want to understand whether this approach might help achieve a 'functional cure,' where the virus becomes undetectable.
Most people with chronic hepatitis B need lifelong treatment, and current options don't work for everyone. This trial is exploring whether this new medication combination can help clear the virus more completely and possibly allow people to stop taking medicine permanently.
You likely qualify if…
You likely don't qualify if…
You will visit the NIH Clinical Center for screening and a baseline liver biopsy. Then you'll receive injections of the medication under your skin every 4 weeks for 12 weeks, followed by a second liver biopsy. After that, a second medication will be added for 12 weeks, then continued alone for another 12 weeks. Throughout the 36-week treatment period and for 24 weeks after, you'll have regular blood tests, occasional liver sampling, and follow-up visits to monitor your response and any side effects.
AI-generated summary from trial data · Jun 21, 2026 · Not medical advice
United States